Verrica Pharmaceuticals reports results from its study investigating Lytix’s lead drug candidate LTX-315 in patients with basal cell carcinoma (BCC).
In short, the result showed that 86 percent overall reduction of tumor size, 51 percent complete clearance rate of basal cell carcinomas (total removal), and 71 percent average reduction in tumor size of patients with residual carcinomas, reports Lytix Biopharma.
The potential to be utilized as a first-line therapy
Based on the phase II data and primary market research, Verrica states that Lytix’s leading drug candidate “has the potential to be utilized as a first-line therapy”. The preliminary efficacy results were retrieved from 93 patients and included a highly favorable safety profile with no severe adverse events.
“Together with our partner Verrica, we’re immensely proud of these results, showing that our lead drug candidate LTX-315 has a powerful anticancer effect in basal cell carcinoma. It has the potential to be used either alone or in combination with surgery in early lines of treatment in this vast cancer population. This is a major leap for our unique treatment technology and an instrumental milestone in progressing LTX-315 towards commercialization,” says Øystein Rekdal, CEO of Lytix Biopharma.
Photo of Oystein Rekdal, CEO, Lytix Biopharma
